# POST-CABGDM: Empagliflozin in Perioperative CABG

> **NCT04523064** · PHASE4 · COMPLETED · sponsor: **University of Sao Paulo General Hospital** · enrollment: 155 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Coronary Artery Disease
- Coronary Artery Bypass Surgery
- Acute Kidney Injury

## Interventions

- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT04523064
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523064, "POST-CABGDM: Empagliflozin in Perioperative CABG". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04523064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*